[Clinical evaluation of bencyclane].
D000293:Adolescent; D000328:Adult; D000368:Aged; D001341:Autonomic Nervous System / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D003327:Coronary Disease / Q000188:drug therapy; D003508:Cycloheptanes / Q000627:therapeutic use*; D005650:Fumarates / Q000627:therapeutic use; D006261:Headache / Q000188:drug therapy; D006801:Humans; D007269:Injections, Intra-Arterial; D008875:Middle Aged; D010276:Parasympatholytics / Q000627:therapeutic use*; D011437:Propylamines / Q000627:therapeutic use*; D012140:Respiratory Tract Diseases / Q000188:drug therapy; D013035:Spasm / Q000188:drug therapy; D014149:Tranquilizing Agents / Q000494:pharmacology; D014456:Ulcer / Q000188:drug therapy; D014652:Vascular Diseases / Q000188:drug therapy*; D014655:Vascular Resistance
D003508:Cycloheptanes; D005650:Fumarates; D010276:Parasympatholytics; D011437:Propylamines; D014149:Tranquilizing Agents
Klinische Beurteilung von Bencyclan.